Just months af­ter lay­offs and push­ing eye ther­a­py, Pro­QR to of­fload eye port­fo­lio in piv­ot to RNA-edit­ing

Near­ly four months af­ter join­ing dozens of oth­er biotechs in lay­ing off em­ploy­ees and trim­ming down its pipeline, Pro­QR is back at it again.

The Dutch biotech an­nounced ear­ly Thurs­day that it will be look­ing for a part­ner to take the com­pa­ny’s oph­thal­mol­o­gy port­fo­lio fur­ther in­to clin­i­cal tri­als. The com­pa­ny had said in a state­ment that af­ter a piv­otal tri­al fail­ure back in Feb­ru­ary for lead can­di­date se­po­farsen, the EMA had said that the biotech would need to con­duct an ad­di­tion­al piv­otal clin­i­cal tri­al be­fore fil­ing for ap­proval. And that tri­al won’t be done by Pro­QR.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER